Aluminum Phosphate
Phase 1Biologic
Aluminum phosphate is used as an ingredient in vaccines to help the body's immune system respond better to the vaccine, and it's also used as an antacid to relieve heartburn and stomach upset.[1] Aluminum Phosphate is currently being investigated across 1 indication[3], with its most advanced program in Phase 1.[1]
Aluminum Phosphate is one of 27 biologic programs targeting COVID-19. It is currently in Phase 1.
1
Indications
24
Total Trials
2
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Benadryl
PParkedale
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunogenicity7 trials
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001052·110 enrolled
Show 4 more trials
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001044·80 enrolled
A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001053·36 enrolled
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001042·112 enrolled
Effectiveness3 trials
The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00031109·10 enrolled
Adult2 trials
Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00382980·308 enrolled
Phase I STEBVax in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00974935·29 enrolled
Flu Vaccine1 trial
H5 Adult - Chiron Study of Bird Flu Vaccine
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00280033·394 enrolled
10 more indications
Thyroid1 trial
Type 1 Diabetes1 trial
Subarachnoid Hemorrhage1 trial
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
Completed·EEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez·Phase 3·NCT05131295·49 enrolled
HIV-11 trial
Vaccine1 trial
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00294099·600 enrolled
Adjuvant1 trial
H5 Vaccine Alone or With Adjuvant in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00296634·600 enrolled
Malaria1 trial
Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00347555·80 enrolled
HIV Infections1 trial
COVID-191 trial
A Phase 1, Open-Label, Safety and Immunogenicity Trial of Boost-2867, an IgG-Fc-RBD Fusion Protein Next Generation SARS-CoV-2 Booster Vaccine, Via Intranasal and Intramuscular Routes in Previously Vaccinated Adults
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07221162·140 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aluminum Phosphate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details